Component Shortage Slows Remediation Of ResMed Ventilator Safety Issue, FDA Says
A malfunction in certain ResMed ventilators may cause the devices to stop delivering therapy, according to the FDA, which says the issue has been linked to five serious injuries and no reported deaths. Patients should continue using their ventilator unless instructed otherwise by their clinicians.
Medtech Insight - July 16, 2026

Executives On The Move: GSK, Sanofi, Merck Alums Take Top Pharma Roles
Recent moves in the industry include C-suite changes at Illumina, internal C-suite appointments at Ovid Therapeutics, plus Moderna gets a new board member.
Scrip - July 16, 2026

Academics Propose Higher UK Vit D Threshold To Expose Reality Of Deficiency
A group of UK academics is calling for the vitamin D deficiency threshold to be doubled to 50nmol/L, a change that would classify over half of adults as deficient and strengthen the case for wider supplementation and fortification.
HBW Insight - July 16, 2026

Abivax Advances R&D Efforts With Valerio RNA pact
Abivax, riding a $920m public offering and regulatory momentum for obefazimod, has teamed up with fellow French RNA biotech Valerio Therapeutics in an immune-mediated inflammation collaboration worth up to €2.4m upfront.
Scrip - July 16, 2026

J&J Blames UK Impella Trial For Abiomed Decline As Q2 Cardiovascular Slips
An unfavorable UK clinical trial on J&J's Impella heart device has moved from the medical literature into the company's quarterly results, with slower procedure volumes dragging Abiomed revenue down 2% in Q2 2026 and pushing Cardiovascular growth below its recent trend.
Medtech Insight - July 16, 2026

Deals In Depth: June 2026
Sixteen $1bn+ alliances were penned in June, and seven exceeded $2bn. In the top alliance by deal value, Haisco Pharmaceutical Group?signed a potential $3.05bn collaboration with?Eli Lilly to develop medicines across multiple therapeutic areas.
In Vivo - July 16, 2026

Merck & Co.’s Lipfendra Brings First Oral PCSK9 To Market
The company’s oral PCSK9 inhibitor enlicitide was approved by FDA, a key pillar in the company’s cardiovascular pipeline renaissance.
Scrip - July 16, 2026

Hyloris Revives China Ambitions With New Maxigesic Partner
Hyloris’ partner AFT has replaced Maxigesic IV’s previous China licensee with Chengdu Tongde, which will fund development, seek approval and manufacture the product, while Hyloris retains a minority share of future royalties.
Generics Bulletin - July 16, 2026

Reports: Viatris To Exit Biocon As Biosimilars Competition Reopens Globally
Viatris’ Mylan has sold approximately 92 million Biocon shares in a block deal, fully exiting the Indian manufacturer and completing the monetization of its former Biocon Biologics stake.
Generics Bulletin - July 16, 2026

Teva Wins Chance To Prove Lilly Delayed Teriparatide Launch
The Seventh Circuit has revived Teva’s claim that Lilly breached a Forteo settlement by delaying generic entry, ruling that the agreement’s duration could not be resolved at the dismissal stage.
Generics Bulletin - July 16, 2026

Change On The Horizon As Sandoz Shakes Up Management Team
Glenn Gerecke has been replaced as president of generics manufacturing and supply at Sandoz, while North America president Keren Haruvi and transformation and growth head Simon Goeller have been given new responsibilities. What do these changes tell us about Sandoz’s business priorities?
Generics Bulletin - July 16, 2026

Paying More, Choosing Less: A Decade Of Deal Data
Evaluate data on nearly 1,200 acquisitions shows pharma writing larger checks for earlier-stage, less-proven assets – and concentrating them in fewer modalities. The 2019 playbook on price, stage and modality no longer holds.
In Vivo - July 16, 2026

DAC Plots To Come From Behind In Small Cell Lung Cancer ADC Race
As DAC plans a Phase III registrational study in China for its CD56-targeting antibody-drug conjugate DXC006 for second- or later-line ES-SCLC, it sees low toxicity as a potential key advantage for the relative latecomer.
Scrip - July 16, 2026

House Democrats Want GAO Study Of US FDA User Fee Spending On Layoffs
Rep. Frank Pallone questioned whether user fees could be spent on severance and other costs related to staff departures.
HBW Insight - July 16, 2026

US OTC Monograph Guidance On Formal Meetings Adds IND Studies, Clarifies ‘Joint’ Requests
Final guidance features revisions from 2022 draft including addressing meetings with agency officials to obtain advice on IND applications to support determinations of whether an OTC drug is GRASE, and clarification of eligible participants in “joint meetings.”
HBW Insight - July 16, 2026

Givaudan, IFF Invest In Scent-Extending Tech; Fragrance Roundup
Givaudan is investing in encapsulation technology that will enhance scent performance, as International Flavors & Fragrances focuses on light-activated fragrance technology and dsm-firmenich rolls out its immersive art-and-fragrance installation.
HBW Insight - July 16, 2026